Evaluation of applicability of CETP gene mutation as the predictor of cardiovascular disease in Bangladeshi population

Paper Details

Research Paper 07/04/2023
Views (447) Download (55)
current_issue_feature_image
publication_file

Evaluation of applicability of CETP gene mutation as the predictor of cardiovascular disease in Bangladeshi population

Md. Mahbubur Rahman, Ratna Khatun, Md. Jahangir Alam, Farhana Yesmin, Masuma Hossina Jarin, Md. Mahmudul Hasan Maruf, Md. Zahidus Sayeed, Md. Anwarul Kabir Bhuiya, Md. Abu Reza
Int. J. Biosci.22( 4), 64-71, April 2023.
Certificate: IJB 2023 [Generate Certificate]

Abstract

Cholesterol ester transfer protein (CETP) is a hydrophobic glycoprotein that mediates the transfer of cholesteryl ester from HDL in exchange for triglycerides in apolipoprotein B100 containing lipoproteins. Several studies showed genetic mutation in different populations in the CETP gene contributes to the manifestation of cardiovascular diseases (CVD) in that population. Exon 15 is the hotspot of CETP gene mutation. Therefore, the aim of the present study is to search for genetic mutation of CETP gene at exon 15 in the Bangladeshi population. In this study, total of 200 subjects including 100 CVD patients were recruited. Blood samples were drawn from the participants for the assessment of total cholesterol, LDL, HDL and triglycerides. Socio-demographic analyses were carried out among the CVD patients and control. DNA was extracted from the blood sample of selected patients and control individuals. Exon 15 of the CETP gene was amplified through PCR and was subjected to Sanger sequencing. Multiple sequence alignment was carried out to screen mutations. Sequence analysis revealed no mutation at exon 15 of the CETP gene. Thus, mutation of CETP in exon 15 did not provide any significant information for the prediction of CVD in the Bangladeshi population.

VIEWS 83

Agerholm-Larsen B, Tybjærg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. 2000. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation 102(18), 2197–2203. https://doi.org/10.1161/01.CIR.102.18.2197

Al Mamun M, Rumana N, Pervin K, Azad MC, Shahana N, Choudhury SR, Zaman MM, Turin TC. 2016. Emerging burden of cardiovascular diseases in Bangladesh. Journal of Atherosclerosis and Thrombosis 23(4), 365–375. https://doi.org/10.5551/jat.30445

Ali KM, Wonnerth A, Huber K, Wojta J. 2012. Cardiovascular disease risk reduction by raising HDL cholesterol – Current therapies and future opportunities. In British Journal of Pharmacology 167(6), 1177–1194 p. Wiley Online Library. https://doi.org/10.1111/j.1476-5381.2012.02081.x

Armitage J, Holmes M, Preiss D. 2019. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week. In Journal of the American College of Cardiology  73(4), 477–487 p. American College of Cardiology Foundation Washington, DC. https://doi.org/10.1016/j.jacc.2018.10.072

Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. 2003. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. In Arteriosclerosis, Thrombosis, and Vascular Biology 23(2), 160–167 p. Am Heart Assoc. https://doi.org/10.1161/01.ATV.0000054658.91146.64

Bowman L, Chen F, Sammons E, Hopewell JC, Wallendszus K, Stevens W, Valdes-Marquez E, Wiviott S, Cannon CP, Braunwald E, Collins R, Landray MJ, Hopewell JC, Jiang L, Armitage J, Haynes R, Maggioni AP, Ertl G, Angermann CE, Wallendszus K. 2017. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, a. American Heart Journal 187, 182–190. https://doi.org/10.1016/j.ahj.2017.02.021

Dullaart RPF, Sluiter WJ. 2008. Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: An updated analysis. Pharmacogenomics 9(6), 747–763. https://doi.org/10.2217/14622416.9.6.747

Jung H, Lee KS, Choi JK. 2021. Comprehensive characterisation of intronic mis-splicing mutations in human cancers. Oncogene 40(7), 1347–1361. https://doi.org/10.1038/s41388-020-01614-3

Kumari A, Sedehizadeh S, Brook JD, Kozlowski P, Wojciechowska M. 2022. Differential fates of introns in gene expression due to global alternative splicing. In Human Genetics 141(1), 31–47 p, Springer. https://doi.org/10.1007/s00439-021-02409-6

Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. 2017. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: The strong heart study. Diabetes Care 40(4), 529–537. https://doi.org/10.2337/dc16-1958

Maïga SF, Kalopissis AD, Chabert M. 2014. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes. In Biochimie 96(1), 56–66 P. Elsevier. https://doi.org/10.1016/j.biochi.2013.08.027

Nag T, Ghosh A. 2013. Cardiovascular disease risk factors in Asian Indian population: A systematic review. In Journal of Cardiovascular Disease Research 4(4), 222–228 p. Elsevier. https://doi.org/10.1016/j.jcdr.2014.01.004

Piko P, Fiatal S, Werissa NA, Bekele BB, Racz G, Kosa Z, Sandor J, Adany R. 2020. The effect of haplotypes in the CETP and LIPC genes on the triglycerides to HDL-C ratio and its components in the roma and hungarian general populations. Genes, 11(1), 56. https://doi.org/10.3390/genes11010056 

Pirim D, Wang X, Niemsiri V, Radwan ZH, Bunker CH, Hokanson JE, Hamman RF, Barmada MM, Demirci FY, Kamboh MI. 2016. Resequencing of the CETP gene in American whites and African blacks: Association of rare and common variants with HDL-cholesterol levels. Metabolism: Clinical and Experimental 65(1), 36–47. https://doi.org/10.1016/j.metabol.2015.09.020

Qasim A, Rader D. 2006. Human genetics of variation in high-density lipoprotein cholesterol. In Current Atherosclerosis Reports 8(3), p 198–205). Springer. https://doi.org/10.1007/s11883-006-0074-0

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP. 2020. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol 76(25), 2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010

Sakai N, Yamashita S, Hirano K, ichi Menju M, Arai T, Kobayashi K, Ishigami M, Yoshida Y, Hoshino T, Nakajima N, Kameda-Takemura K, Matsuzawa Y. 1995. Frequency of exon 15 missense mutation (442D:G) in cholesteryl ester transfer protein gene in hyperalphalipoproteinemic Japanese subjects. Atherosclerosis 114(2), 139–145. https://doi.org/10.1016/0021-9150(94)05477-Z

Takahashi K, Jiang XC, Sakai N, Yamashita S, Hirano K, Bujo H, Yamazaki H, Kusunoki J, Miura T, Kussie P, Matsuzawa Y, Saito Y, Tall A. 1993. A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins. Journal of Clinical Investigation 92(4), 2060–2064. https://doi.org/10.1172/JCI116802

Thompson JF, Durham LK, Lira ME, Shear C, Milos PM. 2005. CETP polymorphisms associated with HDL cholesterol may differ from those associated with cardiovascular disease. Atherosclerosis 181(1), 45–53. https://doi.org/10.1016/j.atherosclerosis.2005.01.05

Wang J, Wang LJ, Zhong Y, Gu P, Shao JQ, Jiang Sen S, Gong Bin J. 2013. CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population. Lipids in Health and Disease 12(1), 1–5. https://doi.org/10.1186/1476-511X-12-176

Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR. 1996. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. Journal of Clinical Investigation 97(12), 2917–2923. https://doi.org/10.1172/JCI118751.